Study Investigating Administration of Prevenar for Post-Marketing Surveillance

Back to Search
Print
Bookmark Trial

NCT00195390

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Seoul, , 100-380, Korea, Republic of
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-9 weeks
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Infants and children aged 6 weeks to 9 years, provided the conditions pertaining to contraindications, warnings, precautions, and interactions stated in the package insert do not apply.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Hypersensitivity to latex or to any component of the vaccine, including diphtheria
toxoid


- Suffering from a current or recent febrile illness.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pneumococcal InfectionsStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India
NCT00452790
  1. Sector-12, Chandigarh
  2. Sector-32 B, Chandigarh
  3. Bangalore, Karnataka
  4. Bangalore, Karnataka
  5. Mumbai, Maharashtra
  6. Pune, Maharashtra
  7. Pune, Maharashtra
  8. Pune, Maharashtra
  9. Rajinder Nagar, New Delhi
  10. Ludhiana, Punjab
  11. Chennai, Tamil Nadu
  12. Vellore, Tamil Nadu
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal InfectionsStudy Investigating Administration of Prevenar for Post-Marketing Surveillance
NCT00195390
  1. Seoul,
ALL GENDERS
6 Weeks+
years
MULTIPLE SITES
Pneumococcal InfectionsStudy to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants
NCT03550313
  1. Miami, Florida
  2. Houston, Texas
  3. Saint George, Utah
  4. Harrisburg, Arkansas
  5. Anaheim, California
  6. Downey, California
  7. Huntington Beach, California
  8. Madera, California
  9. Ontario, California
  10. Paramount, California
  11. San Diego, California
  12. Boynton Beach, Florida
  13. DeLand, Florida
  14. Homestead, Florida
  15. Miami Lakes, Florida
  16. Miami, Florida
  17. Miami, Florida
  18. Columbus, Georgia
  19. Park Ridge, Illinois
  20. Mishawaka, Indiana
  21. Louisville, Kentucky
  22. Nicholasville, Kentucky
  23. Baton Rouge, Louisiana
  24. Metairie, Louisiana
  25. Shreveport, Louisiana
  26. Shreveport, Louisiana
  27. Silver Spring, Maryland
  28. Boston, Massachusetts
  29. Kansas City, Missouri
  30. Omaha, Nebraska
  31. East Syracuse, New York
  32. Liverpool, New York
  33. Boone, North Carolina
  34. Winston-Salem, North Carolina
  35. Winston-Salem, North Carolina
  36. Dayton, Ohio
  37. Erie, Pennsylvania
  38. Charleston, South Carolina
  39. Greenville, South Carolina
  40. Sioux Falls, South Dakota
  41. Sioux Falls, South Dakota
  42. Sioux Falls, South Dakota
  43. Sioux Falls, South Dakota
  44. Sioux Falls, South Dakota
  45. Sioux Falls, South Dakota
  46. Kingsport, Tennessee
  47. Houston, Texas
  48. Houston, Texas
  49. Keller, Texas
  50. San Antonio, Texas
  51. Spring, Texas
  52. Spokane, Washington
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal InfectionsTrial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
NCT03512288
  1. Fayetteville, Arkansas
  2. Downey, California
  3. Huntington Beach, California
  4. Oakland, California
  5. Ontario, California
  6. Sacramento, California
  7. San Jose, California
  8. Santa Clara, California
  9. Haughton, Louisiana
  10. Metairie, Louisiana
  11. Shreveport, Louisiana
  12. Shreveport, Louisiana
  13. Omaha, Nebraska
  14. East Syracuse, New York
  15. Boone, North Carolina
  16. Raleigh, North Carolina
  17. Cincinnati, Ohio
  18. Cincinnati, Ohio
  19. Cincinnati, Ohio
  20. Cincinnati, Ohio
  21. Cincinnati, Ohio
  22. Dayton, Ohio
  23. South Euclid, Ohio
  24. Tulsa, Oklahoma
  25. Erie, Pennsylvania
  26. Hermitage, Pennsylvania
  27. Philadelphia, Pennsylvania
  28. Charleston, South Carolina
  29. Charleston, South Carolina
  30. North Charleston, South Carolina
  31. Galveston, Texas
  32. San Antonio, Texas
  33. Layton, Utah
  34. Murray, Utah
  35. Roy, Utah
  36. South Jordan, Utah
  37. Syracuse, Utah
  38. Charlottesville, Virginia
  39. Charlottesville, Virginia
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Investigating Administration of Prevenar for Post-Marketing Surveillance
Official Title Investigation of Prevenar (Pneumococcal 7-Valent Conjugate Vaccine) Administration for Post-Marketing Surveillance
Brief Summary

The purpose of this study is to identify the following problems and questions with respect to the safety of Pneumococcal 7-Valent Conjugate Vaccine (Diphtheria CRM 197 Protein), Prevenar, during the post-marketing period in Korea, as required by Korea Food and Drug Administration (KFDA) regulations.

  1. Adverse reactions (especially serious adverse reactions)
  2. Incidences of adverse reactions under routine vaccine use
  3. Factors that may affect the safety of the vaccine
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Primary care clinic, secondary and tertiary medical centers
Condition Pneumococcal Infections
Intervention Biological: Prevenar
Prevenar 0.5ml/ Vial and PFS
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Estimated Enrollment
 (submitted: September 13, 2005)		600
Original Enrollment Same as current
Actual Study Completion Date July 2008
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

  • Infants and children aged 6 weeks to 9 years, provided the conditions pertaining to contraindications, warnings, precautions, and interactions stated in the package insert do not apply.

Exclusion Criteria:

  • Hypersensitivity to latex or to any component of the vaccine, including diphtheria toxoid
  • Suffering from a current or recent febrile illness.
Sex/Gender
Sexes Eligible for Study:All
Ages 6 Weeks to 9 Years   (Child)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Korea, Republic of
Removed Location Countries  
 
Administrative Information
NCT Number NCT00195390
Other Study ID Numbers 0887X-101583
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date September 2008